ClinicalTrials.Veeva

Menu

Phacoemulsification at High IOP and Physiologic IOP: Impact on Anterior and Posterior Segment Physiology

M

Matthew Rauen

Status

Completed

Conditions

Nuclear Cataract

Treatments

Other: High IOP
Other: Low IOP

Study type

Observational

Funder types

Other

Identifiers

NCT05765201
Alcon IIT # 75098433

Details and patient eligibility

About

The purpose of this study is to investigate the anterior and posterior structure and functional changes and vascular alterations when performing phacoemulsification at high IOP vs low, more physiological IOP using Centurion® Vision System with Active Sentry® handpiece. These devices are approved by the US Food and Drug Administration (FDA).

Full description

To investigate the anterior and posterior physiological changes when performing phacoemulsification at high IOP vs low, more physiologic IOP using Centurion® Vision System with Active Sentry® handpiece

Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye

Operating at lower, more physiological IOP using Active Sentry® handpiece during cataract surgery will use less BSS fluid usage. (Lower IOP settings are also expected to result in less subclinical changes).

Enrollment

27 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • No prior ocular surgery including corneal refractive surgery
  • Bilateral visually significant cataract, similar in density (LOCS III grade 2+), undergoing uncomplicated cataract surgery
  • Equal dilated pupil size ≥6mm, no use of pupil expansion devices
  • Unremarkable systemic health but inclusive of controlled type II diabetes and hypertension with normal OCT angiography at baseline
  • A1C ≤ 8% on single monotherapy or lifestyle adjustments
  • To maintain high sensitivity/specificity, patients to fall under OCT normative database:
  • Axial length 22-26mm
  • Refractive error between -5.00D to +5.00D
  • Cylinder ≤ 3.00D
  • Normal K values <47.00D
  • Axial eye length cannot vary by more than 0.4 mm in an individual patient
  • Normal CCT range 540µm ± 50

Exclusion criteria

  • H/o corneal disease or dystrophies
  • Media opacification for reasons other than cataract
  • Compromised zonular integrity or stability
  • Retinal and retinal vascular pathologies, age-related macular degeneration
  • Glaucoma
  • Patients with uncontrolled systematic diseases; including hypertension, diabetes, systemic cardiovascular diseases and hematological diseases

Trial design

27 participants in 2 patient groups

High IOP
Description:
Eyes in this arm will maintain an IOP of 65mmHg throughout the cataract surgery.
Treatment:
Other: High IOP
Low IOP
Description:
Eyes in this arm will maintain an IOP of 28mmHg throughout the cataract surgery.
Treatment:
Other: Low IOP

Trial contacts and locations

1

Loading...

Central trial contact

Robyn A Kohler, RN; Hillery Joiner

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems